For ALK positive NSCLC, where in treatment sequencing do you utilize lorlatinib?

Topics: Thoracic Malignancies • Medical Oncology

Does the recent CROWN trial affect your first line treatment decision?

Answer from: Medical Oncologist at Community Practice

The CROWN trial was one of the most important trials reported in the field of lung cancer in 2020. The results of this trial with a median follow up of 18 months were presented by Dr. Ben Solomon at ESMO 2020. The HR for Investigator assessed PFS in this trial with lorlatinib was 0.21 (0.28- Indepen...

Comments

Medical Oncologist at University of Alabama School of Medicine
Thank you Dr. @Shirish M. Gadgeel for such an exce...

Medical Oncologist at Henry Ford Cancer Institute/Henry Ford Hospital
That is the primary reason to be cautious. Otherwi...

Related Questions